{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:47:11Z","timestamp":1784252831888,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,4]]},"DOI":"10.7759\/cureus.68650","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T15:55:20Z","timestamp":1725465320000},"source":"Crossref","is-referenced-by-count":8,"title":["Unraveling the Nexus Between Ambient Air Pollutants and Cardiovascular Morbidity: Mechanistic Insights and Therapeutic Horizons"],"prefix":"10.7759","author":[{"given":"Vishal","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Vellapandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/srep38328","article-title":"Acute effects of nitrogen dioxide on cardiovascular mortality in Beijing: an exploration of spatial heterogeneity and the district-specific predictors","volume":"6","author":"Luo K","year":"2016","unstructured":"Luo K, Li R, Li W, et al.. Acute effects of nitrogen dioxide on cardiovascular mortality in Beijing: an exploration of spatial heterogeneity and the district-specific predictors. Sci Rep. 2016, 6:38328. 10.1038\/srep38328","journal-title":"Sci Rep"},{"key":"ref2","unstructured":"Ozone pollution is linked with increased hospitalisations for cardiovascular disease. (2023). Accessed. July 2024: https:\/\/www.escardio.org\/The-ESC\/Press-Office\/Press-releases\/ozone-pollution-is-linked-with-increased-hospitalisation...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HCR.0000000000000733","article-title":"Carbon monoxide and its effects on those with cardiovascular disease","volume":"42","author":"Gaalema DE","year":"2022","unstructured":"Gaalema DE. Carbon monoxide and its effects on those with cardiovascular disease. J Cardiopulm Rehabil Prev. 2022, 42:E55-6. 10.1097\/HCR.0000000000000733","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112906","article-title":"The role of inflammation in cardiovascular disease","volume":"23","author":"Henein MY","year":"2022","unstructured":"Henein MY, Vancheri S, Longo G, Vancheri F. The role of inflammation in cardiovascular disease. Int J Mol Sci. 2022, 23:10.3390\/ijms232112906","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00036.2017","article-title":"Sources of vascular nitric oxide and reactive oxygen species and their regulation","volume":"99","author":"Tejero J","year":"2019","unstructured":"Tejero J, Shiva S, Gladwin MT. Sources of vascular nitric oxide and reactive oxygen species and their regulation. Physiol Rev. 2019, 99:311-79. 10.1152\/physrev.00036.2017","journal-title":"Physiol Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-015-9334-y","article-title":"Air pollution-induced vascular dysfunction: potential role of endothelin-1 (ET-1) system","volume":"16","author":"Finch J","year":"2016","unstructured":"Finch J, Conklin DJ. Air pollution-induced vascular dysfunction: potential role of endothelin-1 (ET-1) system. Cardiovasc Toxicol. 2016, 16:260-75. 10.1007\/s12012-015-9334-y","journal-title":"Cardiovasc Toxicol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/B0-12-370879-6\/00091-0","article-title":"Coagulation Cascade | Tissue Factor","author":"Rao LV","year":"2006","unstructured":"Rao LV, Pendurthi U. Coagulation Cascade | Tissue Factor. Laurent GJ, Shapiro SD (ed): Acad Press, Cambridge (MA); 2006. 10.1016\/B0-12-370879-6\/00091-0"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11101958","article-title":"Roles of oxidative stress and inflammation in vascular endothelial dysfunction-related disease","volume":"11","author":"Higashi Y","year":"2022","unstructured":"Higashi Y. Roles of oxidative stress and inflammation in vascular endothelial dysfunction-related disease. Antioxidants (Basel). 2022, 11:10.3390\/antiox11101958","journal-title":"Antioxidants (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320916823","article-title":"Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019 (COVID-19)","volume":"27","author":"Lippi G","year":"2020","unstructured":"Lippi G, Henry BM, Sanchis-Gomar F. Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019 (COVID-19). Eur J Prev Cardiol. 2020, 27:906-8. 10.1177\/2047487320916823","journal-title":"Eur J Prev Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-040617-013757","article-title":"E-cigarettes: use, effects on smoking, risks, and policy implications","volume":"39","author":"Glantz SA","year":"2018","unstructured":"Glantz SA, Bareham DW. E-cigarettes: use, effects on smoking, risks, and policy implications. Annu Rev Public Health. 2018, 39:215-35. 10.1146\/annurev-publhealth-040617-013757","journal-title":"Annu Rev Public Health"},{"key":"ref11","unstructured":"E-cigarettes and cardiovascular health. the risks of vaping. (2023). Accessed: July 2024: https:\/\/www.thecardiologyadvisor.com\/features\/e-cigarettes-and-cardiovascular-health-risks-of-vaping\/."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030178","article-title":"Association of cannabis use with cardiovascular outcomes among US adults","volume":"13","author":"Jeffers AM","year":"2024","unstructured":"Jeffers AM, Glantz S, Byers AL, Keyhani S. Association of cannabis use with cardiovascular outcomes among US adults. J Am Heart Assoc. 2024, 13:e030178. 10.1161\/JAHA.123.030178","journal-title":"J Am Heart Assoc"},{"key":"ref13","article-title":"The cardiovascular effects of marijuana: are the potential adverse effects worth the high?","volume":"116","author":"Subramaniam VN","year":"2019","unstructured":"Subramaniam VN, Menezes AR, DeSchutter A, Lavie CJ. The cardiovascular effects of marijuana: are the potential adverse effects worth the high?. Mo Med. 2019, 116:146-53.","journal-title":"Mo Med"},{"key":"ref14","unstructured":"Coronary computed tomography angiography (CCTA). (2024). Accessed. July 2024: https:\/\/www.hopkinsmedicine.org\/health\/treatment-tests-and-therapies\/coronary-computed-tomography-angiography-ccta."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.003951","article-title":"Recent advances in cardiovascular magnetic resonance: techniques and applications","volume":"10","author":"Salerno M","year":"2017","unstructured":"Salerno M, Sharif B, Arheden H, Kumar A, Axel L, Li D, Neubauer S. Recent advances in cardiovascular magnetic resonance: techniques and applications. Circ Cardiovasc Imaging. 2017, 10:10.1161\/CIRCIMAGING.116.003951","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-017-1612-1","article-title":"Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin","volume":"12","author":"Garg P","year":"2017","unstructured":"Garg P, Morris P, Fazlanie AL, et al.. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med. 2017, 12:147-55. 10.1007\/s11739-017-1612-1","journal-title":"Intern Emerg Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113192","article-title":"Brain natriuretic peptide biomarkers in current clinical and therapeutic scenarios of heart failure","volume":"11","author":"Alcidi G","year":"2022","unstructured":"Alcidi G, Goffredo G, Correale M, Brunetti ND, Iacoviello M. Brain natriuretic peptide biomarkers in current clinical and therapeutic scenarios of heart failure. J Clin Med. 2022, 11:10.3390\/jcm11113192","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.031","article-title":"Proteomics research in cardiovascular medicine and biomarker discovery","volume":"68","author":"Lam MP","year":"2016","unstructured":"Lam MP, Ping P, Murphy E. Proteomics research in cardiovascular medicine and biomarker discovery. J Am Coll Cardiol. 2016, 68:2819-30. 10.1016\/j.jacc.2016.10.031","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S288831","article-title":"Safety and tolerability of PCSK9 inhibitors: current insights","volume":"12","author":"Kosmas CE","year":"2020","unstructured":"Kosmas CE, Skavdis A, Sourlas A, Papakonstantinou EJ, Pe\u00f1a Genao E, Echavarria Uceta R, Guzman E. Safety and tolerability of PCSK9 inhibitors: current insights. Clin Pharmacol. 2020, 12:191-202. 10.2147\/CPAA.S288831","journal-title":"Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary R","year":"2017","unstructured":"Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol. 2017, 9:76-91. 10.4330\/wjc.v9.i2.76","journal-title":"World J Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10080322","article-title":"SGLT2 inhibitors vs. GLP-1 agonists to treat the heart, the kidneys and the brain","volume":"10","author":"Rolek B","year":"2023","unstructured":"Rolek B, Haber M, Gajewska M, Rogula S, Pietrasik A, G\u0105secka A. SGLT2 inhibitors vs. GLP-1 agonists to treat the heart, the kidneys and the brain. J Cardiovasc Dev Dis. 2023, 10:10.3390\/jcdd10080322","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.4566","article-title":"Cost-effectiveness of canakinumab for prevention of recurrent cardiovascular events","volume":"4","author":"Sehested TS","year":"2019","unstructured":"Sehested TS, Bjerre J, Ku S, et al.. Cost-effectiveness of canakinumab for prevention of recurrent cardiovascular events. JAMA Cardiol. 2019, 4:128-35. 10.1001\/jamacardio.2018.4566","journal-title":"JAMA Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2018.04.048","article-title":"Stem cell therapies in cardiovascular disease","volume":"33","author":"Terashvili M","year":"2019","unstructured":"Terashvili M, Bosnjak ZJ. Stem cell therapies in cardiovascular disease. J Cardiothorac Vasc Anesth. 2019, 33:209-22. 10.1053\/j.jvca.2018.04.048","journal-title":"J Cardiothorac Vasc Anesth"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281836-unraveling-the-nexus-between-ambient-air-pollutants-and-cardiovascular-morbidity-mechanistic-insights-and-therapeutic-horizons","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T15:55:28Z","timestamp":1725465328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281836-unraveling-the-nexus-between-ambient-air-pollutants-and-cardiovascular-morbidity-mechanistic-insights-and-therapeutic-horizons"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.68650","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}